Publication:
Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).

Simple item page
dc.contributor.authorsAbulkhair, O.; Uslu, R.; Sezgin, C.; Bueyuekberber, S.; Darwish, T.; Isikdogan, A.; Gumus, M.; Dane, F.; Sevinc, A.; Halawani, H.; Uncu, D.; Marrero, N.; Tobler, J.; Soares, C.; Landis, S.; Moraes, E.; Gidekel, R.; Santillana, S.; Nunez, P.; Cagnolati, S.; Rodriguez, J. G.
dc.date.accessioned2022-03-10T17:51:14Z
dc.date.accessioned2026-01-11T10:31:22Z
dc.date.available2022-03-10T17:51:14Z
dc.date.issued2012
dc.identifier.doi10.1158/0008-5472.SABCS12-OT1-1-08
dc.identifier.eissn1538-7445
dc.identifier.issn0008-5472
dc.identifier.urihttps://hdl.handle.net/11424/221465
dc.identifier.wosWOS:000209704900083
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.relation.ispartofCANCER RESEARCH
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleClinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).
dc.typeconferenceObject
dc.type.submeetingabstract
dspace.entity.typePublication
oaire.citation.titleCANCER RESEARCH
oaire.citation.volume72

Files

Collections

Araştırma Çıktıları